Jiyun Park

Jiyun Park

Auto-generated profile, based on publicly available information

Jiyun Park

Department of Microbiology, Institute for Immunology and Immunological Disease, Yonsei University College of Medicine, Seoul, South Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 May 2022 in Virulence
Verified
Journal Article
Open access
JLJUMI LEE
JUMI LEE
JPJiyun Park
Jiyun Park
SRSteven G Reed
Steven G Reed
RCRhea Coler
Rhea Coler
JHJUNG JOO HONG
JUNG JOO HONG
SSSung Jae Shin
Sung Jae Shin
Mycobacterium avium complex (MAC) causing pulmonary disease in humanshas emerged worldwide. Thus, effective strategies simultaneously aiming to prevent MAC infection and accelerate therapeutic efficacy are required. To this end, subunit vaccine-induced protection against a well-defined virulent Mycobacterium avium (Mav) isolate was assessed as a preventative and therapeutic modality in murine models. Mav-derived culture filtrate antigen (CFA) was used as a vaccine antigen with glucopyranosyl lipid A stable emulsion (GLA-SE) or GLA-SE plus cyclic-di-GMP (GLA-SE/CDG), and we compared the immunogenicities, protective efficacies and immune correlates. Interestingly, CFA+GLA-SE/CDG immunization induced greater CFA-specific Th1/Th17 responses in both the lung and spleen than among the tested groups. Consequently, protective efficacy was optimally achieved with CFA+GLA-SE/CDG by significantly reducing bacterial loads along with long-lasting maintenance of antigen-specific Th1/Th17 cytokine-producing multifunctional T cell responses and relevant cytokine productions. Thus, we employed this subunit vaccine as an adjunct to antibiotic treatment. However, this vaccine was ineffective in further reducing bacterial loads. Collectively, our study demonstrates that strong Mav CFA-specific Th1/Th17 responses are critical for preventative protection against Mav infection but may be ineffective or even detrimental in an established and progressive chronic disease, indicating that different approaches to combating Mav infection are necessary according to vaccination purposes.

4 February 2026 in Antimicrobial Agents and Chemotherapy
Verified
Journal Article
Open access
JPJiyun Park
Jiyun Park
SCSangwon Choi
Sangwon Choi
YJYae Rin Jeon
Yae Rin Jeon
LKLee-Han Kim
Lee-Han Kim
JLJUMI LEE
JUMI LEE
SSSung Jae Shin
Sung Jae Shin
The Mycobacterium avium complex (MAC) is the primary cause of pulmonary disease (PD) among nontuberculous mycobacteria, presenting a significant treatment challenge on a global scale. A long-term (≥12 months) three-drug regimen, typically including a macrolide, such as clarithromycin (CLR) or azithromycin, along with rifampicin and ethambutol, is recommended. However, many patients fail to respond adequately to therapy, and some eventually develop macrolide resistance, making the disease even more difficult to treat. This highlights the urgent need for improved therapeutic strategies. Here, we investigated the efficacy of clofazimine (CFZ) and bedaquiline (BDQ), both repurposed from multidrug-resistant tuberculosis therapy, against macrolide-resistant MAC. In macrophage infection assays, both CFZ and BDQ showed significant intracellular inhibitory activity against macrolide-resistant clinical isolates, with CFZ generally exhibiting stronger effects. In a chronic murine model of MAC-caused progressive PD, substitution of CLR with CFZ and BDQ in the treatment regimen led to marked reductions in bacterial loads in both lung and spleen compared with the standard regimen, achieving up to 0.86 log₁₀ CFU reduction in lung and 2.17 log₁₀ CFU in spleen tissues. These findings demonstrate that CFZ and BDQ retain potent activity against macrolide-resistant MAC and highlight their potential as promising components of alternative treatment regimens.

19 December 2023 in Journal of Global Antimicrobial Resistance
Verified
Journal Article
Open access
NKNakwon Kwak
Nakwon Kwak
JPJiyun Park
Jiyun Park
SKSun Ju Kim
Sun Ju Kim
JKJoong-Yub Kim
Joong-Yub Kim
TKTaek Soo Kim
Taek Soo Kim
JYJae-Joon Yim
Jae-Joon Yim
Genetic changes in Mycobacterium abscessus during antibiotic treatment are not fully understood. This study aimed to investigate the genetic changes in M. abscessus in patients receiving antibiotic treatment, and their clinical implications. Pretreatment and 12-month post-treatment M. abscessus isolates were obtained from patients with M. abscessus pulmonary disease. Isolates from each time point were separated into six groups based on their distinctive morphological characteristics. Twenty-four isolates, comprising 12 from patient A exhibiting progressive disease and 12 from patient B demonstrating stable disease, underwent sequencing. Subsequently, minimal inhibitory concentrations (MICs) for the administered antibiotics were measured. Persistent infection with a single strain was observed in patients A and B. During 12 months of treatment, MICs for administered drugs did not generally change over time in either patient and single nucleotide variations (SNV) associated with antimicrobial resistance (rrl, rrs, erm(41), gyrA, gyrB, whiB7 and hflX) were not mutated. Although not significant, 47 and 52 non-synonymous SNVs occurred in M. abscessus from patients A and B, respectively, and the accumulation of these SNVs differed in patients A and B, except for five SNVs. The most variable positions were within a probable NADH-dependent glutamate synthase gene and a putative YrbE family protein gene in patients A and B, respectively. Persistent infections by a single strain of M. abscessus were observed in two patients with different clinical courses. Genetic changes in M. abscessus during antibiotic treatment were relatively stable in these patients. NCT01616745 (ClinicalTrials.gov ID).

16 April 2026 in Cellular and Molecular Life Sciences
Verified
Journal Article
Open access
SCSangwon Choi
Sangwon Choi
JPJiyun Park
Jiyun Park
JHJUNG JOO HONG
JUNG JOO HONG
SSSung Jae Shin
Sung Jae Shin
JLJUMI LEE
JUMI LEE
The Bacillus Calmette-Guérin (BCG) vaccine, the only licensed vaccine against tuberculosis (TB), has played a crucial role in mitigating severe manifestations of the disease, particularly in children. However, its effectiveness against pulmonary TB in adults remains variable, largely due to its limited ability to elicit a sustained antigen-specific TH1 immune response and to generate long-lived tissue-resident memory T cells (TRM) within the lungs. Consequently, innovative strategies that address these immunological shortcomings are needed to enhance BCG immunogenicity and efficacy against pulmonary TB. Recent studies on intravenous (IV)-BCG have emerged as a promising alternative, achieving near-sterilizing immunity in preclinical models such as nonhuman primates by strengthening pulmonary defenses against Mycobacterium tuberculosis (Mtb). This review examines how IV-BCG enhances BCG efficacy through a synergistic network of immunological factors, including trained immunity, effector TH1 cells, lung TRM, inducible bronchus-associated lymphoid tissue (iBALT), and antibody responses. Systemic delivery of IV-BCG induces durable trained immunity, primes robust TH1 and TRM responses in the lungs, may foster iBALT formation for localized protection, and enhances antibody production to reinforce humoral defenses. Drawing on data from preclinical studies, this review highlights how these components interconnect to sustain long-lasting pulmonary protection and offers insights into optimizing BCG-based TB vaccines.

17 October 2023 in Microbiology Spectrum
Verified
Journal Article
Open access
JPJiyun Park
Jiyun Park
LKLee-Han Kim
Lee-Han Kim
JLJu Mi Lee
Ju Mi Lee
SCSangwon Choi
Sangwon Choi
YSYoung-Jin Son
Young-Jin Son
SSSung Jae Shin
Sung Jae Shin
Unsatisfactory outcomes following long-term multidrug treatment in patients with Mycobacterium avium complex (MAC) pulmonary disease have urged us to develop novel antibiotics. Thiopeptides, a class of peptide antibiotics derived from natural products, have potential as drug candidates that target bacterial ribosomes, but drug development has been hampered due to their extremely poor solubility. Here, we evaluated three new compounds (AJ-037, AJ-039, and AJ-206) derived from the thiopeptide micrococcin P2 with enhanced aqueous solubility; the derivatives were generated based on structure-activity relationship analysis. We conducted in vitro drug susceptibility and intracellular antimycobacterial activity testing of the three thiopeptide derivatives against various MAC strains, including macrolide-resistant MAC clinical isolates. These compounds showed low MICs against MAC, similar to that of clarithromycin (CLR). In particular, two compounds, AJ-037 and AJ-206, had intracellular antimycobacterial activities, along with synergistic effects with CLR, and inhibited the growth of MAC inside macrophages. Moreover, these two compounds showed in vitro and intracellular anti-MAC activities against macrolide-resistant MAC strains without showing cross-resistance with CLR. Taken together, the results of the current study suggest that AJ-037 and AJ-206 can be promising anti-MAC agents for the treatment of MAC infection, including for macrolide-resistant MAC strains. IMPORTANCE: Novel antibiotics for the treatment of MAC infection are urgently needed because the treatment outcomes using the standard regimen for Mycobacterium avium complex (MAC) pulmonary disease remain unsatisfactory. Here, we evaluated three novel thiopeptide derivatives (AJ-037, AJ-039, and AJ-206) derived from the thiopeptide micrococcin P2, and they were confirmed to be effective against macrolide-susceptible and macrolide-resistant MAC. Our thiopeptide derivatives have enhanced aqueous solubility through structural modifications of poorly soluble thiopeptides. The thiopeptide derivatives showed minimal inhibitory concentrations against MAC that were comparable to clarithromycin (CLR). Notably, two compounds, AJ-037 and AJ-206, exhibited intracellular antimycobacterial activities and acted synergistically with CLR to hinder the growth of MAC within macrophages. Additionally, these compounds demonstrated in vitro and intracellular anti-MAC activities against macrolide-resistant MAC strains without showing any cross-resistance with CLR. We believe that AJ-037 and AJ-206 can be promising anti-MAC agents for the treatment of MAC infections, including macrolide-resistant MAC strains.

2 September 2026 in Cell & Bioscience
Verified
Journal Article
Open access
PDF file
JLJUMI LEE
JUMI LEE
LKLee-Han Kim
Lee-Han Kim
JPJiyun Park
Jiyun Park
SCSangwon Choi
Sangwon Choi
WJWeonSeok Jung
WeonSeok Jung
SSSung Jae Shin
Sung Jae Shin
Type I interferon (IFN) signaling is associated with detrimental outcomes during Mycobacterium tuberculosis (Mtb) infection, in part through antagonism of